Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study of RO7890597 in Healthy Adult Volunteers

Genentech, Inc. · NCT07797478

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
139
US sites recruiting
1
Study start
August 28, 2026
Record last updated
October 16, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

Being studied: RO7890597; Placebo; Rabeprazole; Itraconazole

Conditions: Healthy Volunteers

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Agreement to adhere to the contraception requirements.
  • Body mass index of 18 to 30 kilograms per square meter (kg/m²).

Exclusion Criteria

  • Pregnant, breastfeeding, or intending to become pregnant during the study or required contraception period.
  • Treatment with investigational biologic therapy within 90 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with investigational non-biologic therapy within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with immunosuppressive medication within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation.
  • Treatment with any vaccine within 14 days prior to initiation of study drug, or within 28 days for a live or live attenuated vaccine.
  • Poor peripheral venous access.
  • Major surgery within 28 days before study drug initiation or planned major surgery during the study.
  • Current infection or recent infection requiring antibiotics as defined in the protocol.
  • History of malignancy within 5 years before screening, except for specified adequately treated cancers.
  • History of clinically significant drug or food allergy.

Recruiting US locations

Study contacts (from the official record)

  • Reference Study ID Number: GA46708 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
All healthy volunteers studies in Kansas →
A Study of RO7890597 in Healthy Adult Volunteers (NCT07797478) | Bored Studies